End-of-day quote
Other stock markets
|
||
- EUR | - |
05-08 | Transcript : Pharming Group N.V., Q1 2024 Earnings Call, May 08, 2024 | |
05-08 | Pharming Group N.V. Provides Revenue Guidance for 2024 | CI |
Sales 2024 * | 266M 289M 394M | Sales 2025 * | 304M 330M 449M | Capitalization | 569M 618M 841M |
---|---|---|---|---|---|
Net income 2024 * | -10M -10.86M -14.78M | Net income 2025 * | 4M 4.34M 5.91M | EV / Sales 2024 * | 1.81 x |
Net cash position 2024 * | 87.65M 95.18M 130M | Net cash position 2025 * | 109M 118M 161M | EV / Sales 2025 * | 1.52 x |
P/E ratio 2024 * |
-52.8
x | P/E ratio 2025 * |
-211
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.67% |
Latest transcript on PHARMING GROUP
Managers | Title | Age | Since |
---|---|---|---|
Sijmen de Vries
CEO | Chief Executive Officer | 65 | 08-10-12 |
Jeroen Wakkerman
DFI | Director of Finance/CFO | 55 | 20-11-15 |
Anurag Relan
CTO | Chief Tech/Sci/R&D Officer | 52 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Pykett
BRD | Director/Board Member | 60 | 20-12-10 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 21-05-18 |
Sijmen de Vries
CEO | Chief Executive Officer | 65 | 08-10-12 |
1st Jan change | Capi. | |
---|---|---|
+34.31% | 693B | |
+29.39% | 584B | |
-2.73% | 372B | |
+20.60% | 332B | |
+6.78% | 294B | |
+14.11% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+9.07% | 168B |